Technological advances have enabled the development of new therapies such as Neuronal Excitability and Signal Amplification (NESA®), which combines low-frequency electrical stimulation and neuromodulation in a non-invasive and highly tolerable manner.
NESA® has been proposed as a treatment for urological conditions associated with bladder dysfunctions, which have a negative impact on patients’ quality of life.

The aim of this study is to evaluate the functional outcomes of NESA® in voiding dysfunction by analyzing its effects on quality of life, symptoms, and continence.

Patients treated between October 2023 and November 2024 were included. Eligible participants presented with idiopathic overactive bladder, acontractile detrusor, anorgasmia or chronic bladder pain syndrome. Patients with adult neurogenic lower urinary tract dysfunction (ANLUTD) were not excluded.

All patients underwent 20 NESA® sessions (2 sessions per week for 10 weeks), following the manufacturer's protocol for each specific condition.

The outcomes assessed were quality of life (SF-36), filling symptoms (OAB-q), incontinence (ICIQ-SF), and potential complications.

Self-administered questionnaires were completed at baseline and after the final treatment session. 

Results were analyzed using Student’s t-test. A p-value < 0.05 was considered statistically significant.

A total of 30 patients were included (9 men and 21 women). Of these, 67% had detrusor overactivity refractory to medical treatment, 13% had chronic bladder pain syndrome, 13% had an acontractile detrusor, and 7% presented with anorgasmia.

Following treatment, a significant improvement was observed in overactive bladder symptoms among patients with overactive or acontractile detrusor (OAB-q, p < 0.05), continence among patients with overactive detrusor and chronic bladder pain syndrome (ICIQ-SF, p < 0.05), and quality of life in patients with overactive detrusor (SF-36, p < 0.05). No complications were reported.

Treatment with NESA® has proven to be an effective and well-tolerated therapeutic tool, significantly improving symptoms and quality of life in patients. However, randomized prospective studies are needed to confirm its role as a standard treatment for the various conditions evaluated.